Skip to main content

Table 1 Associations between LY6D expression and clinicopathological characteristics in Cohorts I and II

From: Lymphocyte antigen 6 superfamily member D is a marker of urothelial and squamous differentiation: implications for risk stratification of bladder cancer

LY6D expression Cohort I Cohort II
0 1 2 P-value 0 1 2 P-value
n(%) 37 (37.0) 20 (20.0) 43 (43.0)   93 (35.8) 92 (36.5) 72 (27.7)  
Age
 Mean, median 73.3, 75,4 70.0, 67.0 68.0, 66.1 0.174 71.1, 71.2 71.2, 70.3 71.8, 72.7 0.674
 range 40.1–88.5 46.0–84.3 39.3–89.9   52.0–85.0 52.9–86.6 51.2–86.8  
Sex
 Male 32 (86.5) 9 (45.0) 33 (76.7) 0.382 72 (77.6) 64 (67.4) 44 (61.1) 0.023
 Female 5 (13.5) 11 (55.0) 10 (23.3)   21 (22.6) 31 (32.6) 28 (38.9)  
pT-stage
 pTa 11 (29.7) 9 (45.0) 12 (42.9) 0.020 26 (28.0) 49 (51.6) 39 (54.2) < 0.001
 pT1 10 (27.0) 4 (20.0) 10 (35.7)   32 (34.4) 29 (30.5) 20 (27.8)  
  ≥ pT2 16 (43.2) 7 (35.0) 6 (21.4)   35 (37.6) 17 (17.9) 13 (18.1)  
Grade
 Low 9 (24.3) 9 (45.0) 29 (67.4) < 0.001 21 (22.6) 61 (64.2) 44 (61.1) < 0.001
 High 28 (75.7) 11 (55.0) 14 (32.6)   72 (77.4) 45 (35.8) 28 (38.9)  
Histology
 Classic   68 (73.1) 81 (85.3) 60 (83.3) 0.016
 Squamous   4 (4.3) 3 (3.2) 7 (9.7)  
 Other variant   21 (22.6) 11 (11.6) 5 (6.9)  
Smoking history
 Regularly   32 (34.4) 33 (34.7) 30 (41.7) 0.184
 Occasionally   5 (5.4) 3 (3.2) 7 (9.7)  
 Former   39 (41.9) 44 (46.3) 26 (36.1)  
 Never   17 (18.3) 15 (15.8) 9 (12.5)  
  1. P-value < 0.05 is considered significant
  2. 0 = Negative LY6D expression, 1 = ≤ 50% positive LY6D expression, 2 = > 50% LY6D expression